High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers

Platelets

Volumn 23, Issue 8, 2012, Pages 586-593

  Marcucci, Rossella ^a,b   Giusti, Betti ^a,b   Paniccia, Rita ^a,b   Gori, Anna Maria ^a,b   Saracini, Claudia ^a   Valente, Serafina ^b   Giglioli, Cristina ^b   Parodi, Guido ^b   Antoniucci, David ^b   Gensini, Gian Franco ^a,b,c   Abbate, Rosanna ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Universitaria Careggi ^*  (Italy)

^c IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

2 polymoprhism; Acute coronary syndrome; Cardiovascular death; Clopidogrel; CYP2C19; High on treatment platelet reactivity; Non fatal myocardial infarction

Indexed keywords

ADENOSINE DIPHOSPHATE; CLOPIDOGREL;

ACUTE CORONARY SYNDROME; ADULT; AGED; ALLELE; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HIGH ON TREATMENT PLATELET REACTIVITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE FUNCTION;

ACUTE CORONARY SYNDROME; ADENOSINE DIPHOSPHATE; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ARYL HYDROCARBON HYDROXYLASES; BLOOD PLATELETS; FEMALE; HEPARIN; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; RISK; SURVIVAL RATE; TICLOPIDINE;

EID: 84866974727     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2012.658106     Document Type: Article

References (29)

1. Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost 2010;2:103-110.
2. Buonamici PG, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, Moschi G, Gori AM, Abbate R, Antoniucci D. Impact of platelet reactivity after clopidogrel administration on drugeluting stent thrombosis. J Am Coll Cardiol 2007;24:2312-2317.
3. Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, Teirstein PS. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008;29:992-1000.
4. Sibbing D, Braun S, Jawansky S, Vogt W, Mehilli J, Schömig A, Kastrati A, von Beckerath N. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 2008;99:121-126.
5. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost. 2005;3:85-92.
6. Frere C, Cuisset T, Quilici J, Camoin L, Carvajal J, Morange PE, Lambert M, Juhan-Vague I, Bonnet JL, Alessi MC. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost. 2007;98:838-843.
7. Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, Simeoni MC, Barragan P, Dignat-George F, Paganelli F. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study. J Am Coll Cardiol. 2008;51:1404-1411.
8. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici PG, Antoniucci D, Abbate R, Gensini GF. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay. A 12-month follow-up. Circulation 2009;119:237-242.
9. Gori AM, Marcucci R, Migliorini A, Valenti R, Moschi G, Paniccia R, Buonamici PG, Gensini GF, Vergara R, Abbate R, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 2008;52:734-739.
10. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005;45:1392-1396.
11. Angiolillo DJ, Ferna'ndez-Ortiz A, Bernardo E, Rami'rez C, Sabaté M, Banuelos C, Herna'ndez-Antoli'n R, Escaned J, Moreno R, Alfonso F, et al. High clopidogrel loading dose during coronary stenting: Effects on drug response and interindividual variability. Eur Heart J 2004;25:1903-1910.
12. Geisler T, Grass D, Bigalke B, Stellos K, Drosch T, Dietz K, Herdeg C, Gawaz M. The Residual platelet aggregation after deployment of intracoronary stent (PREDICT) score. J Thromb Haemost 2008;6:54-61.
13. Migliorini A, Valenti R, Marcucci R, Parodi G, Giuliani G, Buonamici P, Cerisano G, Carrabba N, Gensini GF, Abbate R, et al. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. Circulation 2009;120:2214-2221.
14. Giusti B, Gori AM, Marcucci R, Abbate R. Relation of CYP2C19. 2 loss-of-function polymorphism to the occurrence of stent thrombosis. Expert Opin Drug Metab Toxicol 2010;6:393-407.
15. Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Valente S, Antoniucci D, Abbate R, Gensini GF. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 θ 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in highrisk vascular patients. Pharmacogenet Genomics 2007;17:1057-1064.
16. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Büttner HJ, et al. Cytochrome P450 2C19 681G4A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008;51:1925-1934.
17. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Me'neveau N, Steg PG, Ferrières J, Danchin N, Becquemont L. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-375.
18. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360: 354-362.
19. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, et al. Cytochrome P450 19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet 2009;373:309-317.
20. Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Buonamici P, Antoniucci D, Abbate R, Gensini GF. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol 2009;103:806-811.
21. Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dö rrler K, Morath T, Schömig A, Kastrati A, von Beckerath N. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009;30:916-922.
22. Sofi F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF. Cytochrome P450 2c19 2 polymorphism and ardiovascular recurrences in aptients taking clopidogrel: A meta-analysis. Pharmacogenetics J 2010;11(3):199-206.
23. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CC, Danchin N, Giusti B, Gurbel P, et al. Reduced function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. JAMA 2010;304:1821-1830.
24. Gori AM, Cesari F, Marcucci R, Giusti B, Paniccia R, Antonucci E, Gensini GF, Abbate R. The balance between proand anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients. Atherosclerosis 2009;202:255-262.
25. Cesari F, Marcucci R, Caporale R, Paniccia R, Romano E, Gensini GF, Abbate R, Gori AM. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost 2008;99:930-935.
26. Marcucci R, Gori AM, Paniccia R, Giglioli C, Buonamici P, Antoniucci D, Gensini GF, Abbate R. Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy. Atherosclerosis 2007;195:217-223.
27. US Food and Drug Administration. FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel in patients who are poor metabolizers of the drug. Silver Spring, MD: US Food and Drug Administration. http:// www.fda.gov/Drugs/DrugSafety/Postmarket DrugSafetyInformationforPatientsandProviders/ucm203888.htm (accessed 24 March 2010)
28. Paniccia R, Antonucci E, Gori AM, Marcucci R, Giglioli C, Antoniucci D, Gensini GF, Abbate R, Prisco D. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007;5:1839-1847.
29. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici PG, Antoniucci D, Abbate R, Gensini GF. High on-treatment platelet reactivity by more than one agonist predicts 12-month follow up cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting. Thromb Haemost 2010;104:279-286.